Kailera Therapeutics, INC.
Forward trial catalysts linked to KLRA
CSA tracks 2 forward catalysts for Kailera Therapeutics, INC. across 1 asset, spanning Phase 3. The nearest is a readout expected Feb 2028 (month precision). Confidence across its tracked catalysts breaks down as 2 medium. Tracked indications include Obesity, Obesity With Diabetes, Participants With Obesity and Knee Osteoarthritis.
KLRA in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Kailera Therapeutics, INC. has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
4 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| ribupatide | NCT07284875 catalyst | Phase 3 | Recruiting | 2028-02 | Experimental | Kailera | Obesity; Overweight |
| ribupatide | NCT07284979 | Phase 3 | Recruiting | 2028-03 | Experimental | Kailera | Obesity |
| ribupatide | NCT07284901 catalyst | Phase 3 | Recruiting | 2028-03-27 | Experimental | Kailera | Obesity With Diabetes; Overweight With Diabetes |
| ribupatide | NCT07709910 | Phase 3 | Not yet recruiting | 2028-11 | Experimental | Fujian Shengdi Pharmaceutical Co., Ltd. | Participants With Obesity and Knee Osteoarthritis |
Every trial the CSA sample links to KLRA's tracked assets, including trials another sponsor runs.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →